Bangladesh anti-rheumatic drug market was valued at US$402.375 million in 2020.
A leading factor for Bangladesh’s anti-rheumatic drug market is the country’s poor health infrastructure, which is coupled with an increase in chronic diseases among its older population. Many chronic diseases are caused by obesity which leads to another major health problem - arthritis. In Bangladesh, according to the International Diabetes Federation, around 12.5% of the population between the age of 20 to 79 has diabetes. Moreover, the WHO published the latest data on rheumatoid arthritis deaths in 2020. According to it, rheumatoid arthritis deaths in Bangladesh reached 815, or 0.11% of total deaths. Bangladesh has a world ranking of 18 in age-adjusted deaths.
Increasing cases of musculoskeletal conditions and related disabilities among the adult population
The increasing number of musculoskeletal conditions and related disabilities is alarming. According to a survey undertaken by Bangabandhu Sheikh Mujib Medical University, Dhaka, 30.4% of the 1,843 individuals who took part were diagnosed with musculoskeletal conditions. A patient’s dexterity and functions are affected by the musculoskeletal condition, which thereby, impacts their daily life activities. Lower back pain cases in Bangladesh continue to top the charts of the Institute of Health Matrix. As per the survey, the prevalence of rheumatoid arthritis was found to be 1.6%, and knee osteoarthritis stood at 7.3%. The occupations that demanded heavy physical work like homemaking, cultivation, and rickshaw pulling had higher rates of rheumatic conditions.
Market Restraints
A majority of the Bangladeshi population lives in rural areas; whose data is not easily available. Moreover, there are no nationally representative data on musculoskeletal conditions. Since the rural population tends to treat back aches as a seasonal illness or due to other reasons, they aren’t well-versed in the chronic diseases that are linked with it.
Market Key Developments
The COVID-19 pandemic severely impacted patients with rheumatic diseases, as it put them at a higher risk of catching the COVID-19 virus in comparison to the general population. Furthermore, with the outbreak, it was difficult to provide disease-related medicines, even the production units were shut due to which deliveries were furthermore delayed. However, in the second half of 2020, the market grew with the launch of new products with better investments due to the rising prevalence of arthritis. Several acquisitions and mergers took place for the development of several therapeutics and medications.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2020 | US$402.375 million |
| Growth Rate | CAGR during the forecast period |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Type of Disease, Type of Molecule, And Sales Channel |
| Companies Covered | Incepta Pharmaceuticals Ltd., Novartis AG, Hamdard Laboratories |
| Customization Scope | Free report customization with purchase |
Segmentation